| +0.28 / +0.27%|
The 20 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 112.50, with a high estimate of 136.00 and a low estimate of 80.00. The median estimate represents a +8.14% increase from the last price of 104.03.
The current consensus among 24 polled investment analysts is to Buy stock in Vertex Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.